PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.82%
R&D reduction while CRVO shows 5.59% growth. Joel Greenblatt would examine competitive risk.
-4.34%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
-6.85%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-6.85%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
4.17%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
16.91%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
16.52%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-5.45%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
16.61%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
16.61%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
17.14%
EPS growth while CRVO declines. John Neff would investigate advantages.
17.14%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.